Business
Incannex Provides Shareholder Update Highlighting Clinical Progress, Capital Discipline, and EOY 2025 Strategic Focus
Company outlines continued progress across clinical, regulatory, and capital initiatives positioning for sustained long-term growthMELBOURNE, Australia and NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL)(“Incannex” or the “Company”), a clinical-stage pharmaceutical company developing innovative combination therapies for high-impact medical conditions, provides a shareholder update highlighting recent progress across its clinical and corporate initiatives and o
About this update from Incannex Healthcare Inc.
[{"type":"image","alt":"Incannex Healthcare","displaySize":"","headline":null,"caption":"Incannex Healthcare","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":50,"url":"https://media.zenfs.com/en/globenewswire.com/27f6059234ed425fa359634ca773e7f7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/JtZ_G8jXkVENc6BFL9UpGQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTcwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/27f6059234ed425fa359634ca773e7f7","width":300,"height":50}},"lazy":false},{"type":"text","content":"Company outlines continued progress across clinical, regulatory, and capital initiatives positioning for sustained long-term growth","length":131,"tagName":"p"},{"type":"text","content":"MELBOURNE, Australia and NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL)(“Incannex” or the “Company”), a clinical-stage pharmaceutical company developing innovative combination therapies for high-impact medical conditions, provides a shareholder update highlighting recent progress across its clinical and corporate initiatives and outlining key priorities for the remainder of 2025.","length":419,"tagName":"p"},{"type":"text","content":"Recent Highlights","length":17,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"IHL-42X (OSA) Phase 2 – Statistically significant efficacy, outstanding patient-reported outcomes, and strong safety profile – Incannex reported Phase 2 data for IHL-42X demonstrating statistically significant and clinically meaningful reductions in Apnea-Hypopnea Index (AHI) of up to 83% from baseline, confirming the potential of IHL-42X to meaningfully improve disease severity in obstructive sleep apnea (OSA). The study also showed significant improvements across multiple sleep-quality and fatigue instruments, accompanied by an outstanding safety and tolerability profile.Structured exit interviews reinforced the objective findings, with 57.6% of participants across the study, increasing to 78.6% of those assigned to the low dose group, reporting perceived improvement in their OSA. Of participants reporting an improvement in their OSA, 86.4% described the benefit as meaningful to daily life. Together, we believe these results demonstrate a potential consistent and meaningful treatment effect across both quantitative and qualitative measures","length":106...